FGFR1 and urothelial carcinoma: Recently, the FORT-1 phase II/III trial, led by Sternberg and colleagues,29 demonstrated that rogaratinib and chemotherapy had comparable efficacy and safety in patients with metastatic/advanced urothelial carcinoma exhibiting FGFR1/3 messenger RNA overexpression.